14:44 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest stimulating cholesterol efflux in phagocytes by promoting LXR expression could help treat MS. In a mouse model of lysolecithin-induced MS, cholesterol accumulation in the membranes of lesion-infiltrating phagocytes was...
23:44 , Nov 3, 2017 |  BioCentury  |  Product Development

Liver X factor

Rgenix Inc. is preparing to test its RGX-104 in combination with checkpoint inhibitors after Phase I data confirmed the company’s belief that the liver X receptor agonist depletes suppressive immune cells and increases T cell...
18:57 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

Rgenix reports Phase I data for cancer compound RGX-104

Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led to 4 cases of stable disease among 12 evaluable patients with advanced solid malignancies and lymphoma. RGX-104...
00:46 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

RGX-104: Ph I started

Rgenix began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate oral RGX-104 in about 80 patients. Rgenix has exclusive, worldwide rights to RGX-104 from GlaxoSmithKline. Rgenix Inc., New York, N.Y.  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London,...
17:32 , Jan 11, 2017 |  BC Extra  |  Clinical News

Allergan discloses Phase II miss in LXR program

Allergan plc (NYSE:AGN) said VTP-38543 did not show proof of concept in a Phase II trial to treat atopic dermatitis. Allergan acquired the liver X receptor beta (NR1H2; LXR-b) agonist via its $639 million purchase...
20:31 , Nov 11, 2016 |  BC Week In Review  |  Clinical News

VTP-38543: Ph I/II data

Allergan said that "target engagement was not satisfactorily achieved" in a Phase I/II trial evaluating VTP-38543 in patients with mild to moderate atopic dermatitis. The company said it plans to re-evaluate the concentration and formulation...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Vitae, Allergan deal

Allergan will acquire Vitae for $21 per share in cash in a deal the companies say values Vitae at about $639 million. The price is a 159% premium to Vitae’s close of $8.10 on Sept....
07:00 , Sep 14, 2016 |  BC Extra  |  Top Story

Allergan acquiring Vitae

Allergan plc (NYSE:AGN) is acquiring Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) for $21 per share in cash, or about $639 million. The price is a 159% premium to Vitae's close of $8.10 on Tuesday, before the deal...
01:20 , Jun 16, 2016 |  BC Extra  |  Financial News

Cancer play Rgenix raises $33M

Rgenix Inc. (New York, N.Y.) raised $33 million in a series B round led by new investors Novo A/S (Hellerup, Denmark) and Sofinnova Partners. Existing investors including Partnership Fund for New York City, Alexandria Venture...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

VTP-38543: Phase IIa started

Vitae began a double-blind, dose-escalation, placebo-controlled Phase IIa trial to evaluate topical VTP-38543 twice daily for 4 weeks in about 100 patients. Vitae Pharmaceuticals Inc. (NASDAQ:VTAE), Fort Washington, Pa.   Product: VTP-38543   Business: Dermatology   Molecular...